1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | KHYG1; KHYG |
| Species | Human |
| Cat.No | ABC-TC0506 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
KHYG-1 is a human natural killer (NK) leukemia cell line derived from the peripheral blood of a 45-year-old woman with aggressive NK cell leukemia. This cell line exhibits the morphology of large granular lymphocytes, characterized by a large nucleus, coarse chromatin, prominent nucleoli, and abundant basophilic cytoplasm containing many azurophilic granules. Immunophenotype of KHYG-1 includes markers such as CD2+, CD7+, CD56+, and CD122+, while it is negative for CD1, CD3, CD16, and CD57. KHYG-1 harbors a point mutation in exon 7 of the p53 gene, a mutation also found in primary leukemia cells, making it an ideal model for studying p53-associated leukemogenesis. KHYG-1 cells demonstrate high cytotoxicity against various leukemia cell lines, including EM2, EM3, and HL60, and this cytolytic activity is thought to be mediated by activation receptors such as NKp44, NKG2D, and phosphorylated ERK2. They are valuable for research into NK/T cell differentiation and leukemia therapy.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
KHYG-1 provides a valuable model for studying the biology of normal and malignant NK cells, and leukemogenesis. NK cells have been considered promising candidates for adoptive immunotherapy of malignancies, however, the endogenous NK and lymphokine-activated killer cells show limited cytotoxic activity. Through the investigation of enhanced cytotoxicity of permanent NK cell lines, such as KHYG-1, the limitation of autologous NK cells may be overcome, and NK cells may achieve enhanced cytotoxic potential clinically.
KHYG-1 is a natural killer (NK) leukemia cell line derived from the peripheral blood of a patient with NK cell malignancies. It exhibits the characteristics of large granular lymphocytes, with a prominent nucleus, conspicuous nucleoli, and azurophilic granules in its cytoplasm.
The immunophenotype of KHYG-1 includes several markers: CD1−, CD2+, surface CD3−, cytoplasmic CD3ε+, CD7+, CD8αα+, CD16−, CD25−, CD33+, CD34−, CD56+, CD57−, CD122+, CD132+, and TdT−. This profile is useful for characterizing NK cells and distinguishing them from other cell types.
KHYG-1 has a point mutation in exon 7 of the p53 gene, identical to the mutation found in primary leukemia cells. This mutation is significant because p53 plays a key role in regulating the cell cycle and apoptosis, making it an important target for cancer research.
KHYG-1 provides an excellent model for studying both normal and malignant NK cell biology, as well as leukemogenesis. It is highly cytotoxic to leukemia cell lines like EM2, EM3, and HL60. The investigation of its enhanced cytotoxicity could contribute to overcoming the limitations of autologous NK cells in adoptive immunotherapy and may offer clinical applications for malignancy treatments.
The recommended medium for growing KHYG-1 cells is RPMI 1640 supplemented with 10% Fetal Bovine Serum (FBS). The cells grow in suspension, and proper biosafety level 1 precautions should be observed. Additionally, AcceGen ensures high cell viability and sterility through a strict quality assurance system that includes tests for post-thaw viability, sterility, and cell identification via STR analysis.
